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Abstract
Purpose To evaluate central corneal thickness (CCT) and
intraocular pressure (IOP) in a cohort of acromegalic patients,
and to correlate CCT with serum levels of growth hormone
(GH) and insulin-like growth factor 1 (IGF-1).
Methods Consecutive patients affected by acromegaly
underwent a comprehensive endocrinological and ophthalmo-
logical evaluation, including serum GH and IGF-1 levels,
CCT measured with ultrasonic pachymetry and IOP assessed
with Goldmann applanation tonometry.
Results Fourteen patients with acromegaly and 28 healthy
controls were included in the study. Acromegalic patients
had a statistically higher median CCT (570 μm [range
551.5–638] vs 542.7 μm [range 461.5–610]; p<0.01) and
higher median IOP (17.2 mm Hg [range 14–21] vs 13.7 mm
Hg [range 10.5–19]; p<0.01) than healthy controls. No statis-
tically significant correlation was found among CCT and GH,
CCT and IGF-1, IOP and GH, IOP and IGF-1 in the acrome-
galic group, whereas a statistically significant correlation was
documented between CCT and IOP in the entire cohort
(Spearman’s correlation coefficient: 0.56, p<0.01). However,
when IOP was corrected for CCT no significant difference
was found between the two study groups (p=0.07).
Conclusions Our results suggest that acromegaly is associated
with an increased CCT, which could lead to an overestimation
of IOP readings as determined with Goldmann applanation
tonometry.
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Introduction
Acromegaly is a rare condition usually caused by a growth
hormone (GH)-secreting pituitary adenoma. It is characterized
by excessive growth of the peripheral parts of the body and the
occurrence of chronic complications which may cause impair-
ment of quality of life and increased mortality [1–4]. Frequent
ocular manifestations of acromegaly include visual field de-
fects secondary to chiasmal compression by a pituitary ade-
noma, as well as proptosis, restrictive extraocular myopathy
with diplopia or eyelid edema, and ptosis due to orbital soft
tissue involvement [5, 6].
The presence of ocular abnormalities in children with
pituitary-induced GH excess or deficiency suggests that GH
plays a key role in eye development and growth during
childhood [7, 8]. Moreover, patients with Laron syndrome, a
primary GH receptor insensitivity, who are treated with
insulin-like growth factor 1 (IGF-1) tend to have ocular
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dimensions that resemble the dimensions of healthy controls;
on the contrary, untreated patients tend to have smaller ocular
dimensions [9].
Elevated intraocular pressure (IOP) has been previously
reported in patients with acromegaly [10–12]. A study by
Greco and coworkers [13] showed that, after intravenous
injection of arginine, patients with primary open-angle glau-
coma (POAG) exhibited higher GH levels than healthy con-
trols, thus suggesting a possible relationship between GH
secretion and POAG. Further, other reports have demonstrat-
ed higher values of central corneal thickness (CCT) in acro-
megalic patients than in healthy subjects [12, 14, 15].
It is now widely accepted that in a structurally normal
cornea, higher CCT values may lead to an overestimation of
IOP. A number of studies have therefore investigated the
effect of CCT on Goldmann applanation tonometry (GAT),
the gold standard technique for clinical IOP assessment
[16–20]. Further, there is emerging evidence that CCT might
be a useful tool for identifying patients at a greater risk of
glaucoma progression and more susceptible to IOP-lowering
medications [21, 22].
The aim of the present study was to evaluate CCT and IOP
specifically in a cohort of consecutive acromegalic patients,
and to ascertain whether there is a correlation between CCT
and serum levels of GH and IGF-1.
Materials and methods
This was an observational, case–control study carried out at
the Glaucoma Service of the University of Brescia, Brescia,
Italy, with patients referred to the Endocrine Service of the
Spedali Civili di Brescia, Brescia, Italy. The research protocol
adhered to the tenets of the Declaration of Helsinki.
Participants
Consecutive patients with a confirmed clinical diagnosis of
acromegaly who were under regular clinical follow-up were
enrolled. The diagnosis of acromegaly relied upon evidence of
failure of serum GH suppression to concentrations below
1 ng/ml after a 75-g oral glucose load together with fasting
plasma IGF-1 concentrations above the normal ranges for age
[23]. Patients receiving somatostatin analogue treatment were
evaluated by measurement of serum random GH and IGF-1,
whereas those treated with pegvisomant were evaluated by
serum IGF-1 alone [24]. Acromegaly was considered well-
controlled if IGF-1 values were in the reference range for the
patient’s age. In patients receiving somatostatin analogues,
acromegaly was considered well-controlled if random GH
levels were below 1.0 ng/ml [24]. Median duration of active
disease was estimated on the basis of clinical history. The
duration of uncontrolled disease during medical treatment
was also recorded.
The control group included healthy subjects, matched for
sex and age, recruited from routine visits to the ophthalmolo-
gy outpatient service. Exclusion criteria for eye conditions
were: previous diagnosis of glaucoma or ocular hypertension,
Snellen best-corrected visual acuity less than 0.4, corneal or
other ocular conditions making applanation tonometry unreli-
able, signs or history of ocular diseases, and previous ocular
surgeries including cataract extraction or refractive surgery.
Patients were also excluded if they were using systemic or
topical steroids, or other drugs that could influence IOP levels.
Assessments
Serum GH and IGF-1 levels were collected from the patients’
clinical charts: the mean of the last three measurements was
used for the analysis. GH and IGF-1 were measured with
Immulite 2000 (DPC, Los Angeles, CA, USA). For IGF-1,
normal ranges were 136–244 ng/ml, 107–181 ng/ml and 97–
159 ng/ml for patients aged 20–39 years, 40–59 years, and
60–79 years respectively.
All participants underwent a comprehensive ophthalmo-
logical evaluation that included visual acuity, anterior segment
biomicroscopy, and fundus examination. After topical anes-
thesia with lidocaine 4 % (Alpha Intes, Casoria, Italy), CCT
was measured by means of an ultrasonic pachymeter
(DGH500, DGH Technology Inc., Exton, PA, USA) and,
immediately afterwards, IOP was assessed with GAT
(Haag–Streit, Bern, Switzerland) after a fluorescein-
containing paper strip was lightly stroked at the inferior con-
junctival fornix. The mean value of five CCT measurements
was calculated. Two IOP readings were acquired at 10.00 AM
±1 h; if the two readings differed by >2 mmHg, a third
measurement was obtained, and the mean value of the closest
two readings was used. All CCT and IOP measurements were
done by the same experienced ophthalmologist (IR). Both
eyes of each participant were measured, but only one random-
ly selected eye was analyzed.
The formula suggested by Doughty and Zaman was used
for the correction of IOP based on CCT values for both groups
[18]. This formula assumes a correction of 2.5 mmHg per
50 μm of CCT deviation from 535 μm and was derived with a
meta-analysis approach from hundreds of CCT datasets pub-
lished in the literature over the period from 1968 through mid-
1999.
Statistics
Categorical variables were reported as absolute and relative
frequency, and differences between groups were tested by
means of a Chi-square test. Continuous variables, such as
CCT and IOP, were described using median, minimum and
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maximum values and were tested for normal distribution by
means of a Shapiro–Wilk test. A Mann–Whitney U test was
used to compare continuous variables between groups. Cor-
relations among IOP, CCT, GH, and IGF-1 were evaluated
using the Spearman’s correlation coefficient. Level of signif-
icance was set at 0.05, for a bilateral test. The analyses were
made using SAS software (Statistical Analysis System, ver-
sion 9.4; SAS Institute Inc., Cary, NC, USA).
Results
During the course of the study 14 consecutive patients with
acromegaly and 28 age and sex-matched controls were en-
rolled. All participants were Caucasian. Table 1 shows the
characteristics of the two cohorts.
Eleven of the 14 acromegalic patients had already been
treated with neurosurgery, and all of them required further
treatment (somatostatin analogues and/or pegvisomant) for
the persistence of GH hypersecretion [25]. Two patients were
treated with somatostatin analogues as first-line therapy. At
the time of the study, 12 patients had controlled disease,
whereas the remaining two patients had active acromegaly
notwithstanding different treatments regimens [24]. Median
duration of active disease was 5 years (range: 1–15).
The CCT and IOP values recorded in acromegalic patients
were significantly greater than those documented in the con-
trols (Table 1; p<0.01). However, when IOP was corrected for
CCT [18], no statistically significant difference was detected
between the two groups (Table 1; p=0.07). Moreover, no
significant correlation could be documented between CCT
and GH, CCT and IGF-1, IOP and GH, IOP and IGF-1 in
the acromegalic group (Table 2, Fig. 1 and Fig. 2), whereas a
statistically significant correlation was observed between
CCT and IOP when the entire cohort was considered
(Spearman’s coefficient: 0.56; p<0.01; Table 2, Fig. 3).
Discussion
Our results suggest that acromegalymay be associated with an
increased CCT, and acromegalic patients appear to have
higher IOP values than normal controls. It is well-known that
CCT and other corneal parameters influence GAT readings
because IOP is calculated assuming a fixed CCT of 520 μm,
disregarding inter-individual variability [26]. Consequently,
GAT underestimates IOP in patients with a thin cornea, and
overestimates it in those with a thick cornea. A review of the
literature showed corneal thickness-related deviations in GAT
measurements ranging from 0.11 to 0.71 mmHg for every
10 μm change in CCT [16, 17].
Published evidence to date has indicated that IOP is signif-
icantly increased in acromegalic patients when compared with
healthy subjects [12, 14, 27]. Consequently, acromegaly has
been considered a risk factor for glaucoma development [10,
11]. Polat and coworkers [15] found that acromegaly was
associated with higher levels of IOP, but contrary to our results
did not detect a significant difference in the CCT of patients
with acromegaly compared to controls. The difference with
our data may be attributed to the extreme range of CCT for
Table 1 Characteristics of the
study population
IOP intraocular pressure, CCT
central corneal thickness, GH
growth hormone, IGF-1 insulin-
like growth factor-1
† Chi-square test; *Mann–Whit-
ney U test; ‡According to the for-
mula proposed by Doughty et al.
[18]
Acromegalic patients
(n=14): no. (%)
Control group
(n=28): no. (%)
P-value
Men 7 (50) 12 (42.8) 0.74†
Women 7 (50) 16 (57.1)
Median (range) Median (range) P-value
Age (years) 59.0 (40–71) 58.5 (46–72) 0.48*
Duration of the disease (years) 5 (1–15) – –
GH (ng/ml) 0.9 (0.01–22) – –
IGF-1 (ng/ml) 173.5 (48–513) – –
IOP (mm Hg) 17.2 (14–21) 13.7 (10.5–19) <0.01*
Corrected IOP (mm Hg)‡ 14.8 (11.9–20.1) 13.9 (10.3–18.6) 0.07*
CCT (μm) 570 (551.5–638) 542.7 (461.5–610) <0.01*
Table 2 Spearman’s correlation coefficients for tested variables
Correlation Group N Spearman ρ P-value
CCT - IOP Entire cohort 42 0.56 <0.01
Acromegalic patients 14 0.07 0.8
Healthy subjects 28 0.44 0.01
CCT - GH Acromegalic patients 14 −0.43 0.14
CCT - IGF-1 Acromegalic patients 14 0.23 0.42
IOP - GH Acromegalic patients 14 0.08 0.78
IOP - IGF-1 Acromegalic patients 14 0.21 0.47
CCT central corneal thickness, IOP intraocular pressure, GH growth
hormone, IGF-1 insulin-like growth factor 1
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normal eyes reported in that study (right eye CCT range: 274–
643 μm, left eye CCT range: 267–643 μm). In a recent study
using the Ocular Response Analyzer, Ozkok et al. [28] report-
ed that patients with acromegaly had significantly different
Fig. 2 Scatter-plot of intraocular
pressure vs. growth hormone
serum levels for acromegalic
patients
Fig. 1 Scatter-plot of central
corneal thickness vs. growth
hormone serum levels for
acromegalic patients
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corneal biomechanical properties compared to age- and sex-
matched controls. Specifically, the authors found that acrome-
galic patients had higher corneal hysteresis and corneal resis-
tance factor compared to controls. Although Goldmann-
equivalent readings were higher in the patient group, neither
CCT nor CCT-compensated IOP readings were significantly
different between the two groups. Consequently, in this co-
hort, the apparent differences in Goldmann-equivalent read-
ings could be attributed to acromegaly-induced corneal bio-
mechanical changes. On the other hand, our data suggest that
the higher GAT readings observed in patients with acromegaly
are due to an increased CCT and do not represent an actual
IOP elevation. This is supported by the fact that when IOPwas
corrected for CCT according to the formula proposed by
Doughty and Zaman [18], no significant IOP difference could
be detected between acromegalic and healthy subjects. Our
results corroborate findings by Bramsen et al. [12]. The au-
thors investigated GAT readings and CTT measurements ob-
tained with optical pachymetry in patients with pituitary tu-
mors with (n=13) and without acromegaly (n=14). They
found that both CCT and GAT readings were higher in acro-
megalic patients, but the CCT-corrected IOP readings were
similar in the two groups. Although not explicitly stated by
Bramsen et al. [12], it seems that they used the correction
Fig. 3 Scatter-plot of central
corneal thickness vs. intraocular
pressure for the entire cohort of
the study
Table 3 Summary of previous studies about CCT and IOP in patients affected by acromegaly in comparison with controls
Patients affected by acromegaly Controls
N CCT (mean ± SD, μm) IOP (mean ± SD,
mm Hg)
N CCT (mean ± SD, μm) IOP (mean ± SD,
mm Hg)
Bramsen et al. (1980) [12] 13 patients 561±35 16.9±2.3 14 subjects 526±30 14.7±2.4
Ciresi et al. (2011) [14] 28 patients 567 (559–573.5)* 19 (18–21)* 22 subjects 528.5 (517–535)* 17 (16.5–18)*
Polat et al. (2013) [15] 30 patients 529.2 (471–630) ‡ 16 (11–19) ‡ 21 subjects 537 (487–643) ‡ 13 (9–20) ‡
Ozkok et al. (2014) [28] 46 right eye 545.4±29.2 17.1±4.2† 42 right eye 555.1±28.4 15.1±3.0†
46 left eye 545.8±31.6 17.3±4.2† 42 left eye 557.5±27.1 14.7±3.1†
CCT central corneal thickness, IOP intraocular pressure, *median of the mean (interquartile range); ‡: median of the mean (range) †: Ocular Response
Analyzer Goldmann correlated intraocular pressure
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algorithm suggested by Ehlers et al. [16]. This algorithm
assumes a different correction factor depending on the level
of GAT reading and CCT value. On the other hand, we
assumed a correction of 2.5 mmHg per 50 μm of CCT
deviation from 535 μm as suggested by Doughty and Zaman
[18]. In their study, Bramsen et al. found that the mean CCT-
corrected IOP in pituitary tumor patients with and without
acromegaly was 14.1±2.3 and 14.2±2.4 mmHg respectively.
These results closely match our data: the median CCT-
corrected IOP of acromegalic patients and controls was 14.8
(range: 11.9–20.1) and 13.9 (range: 10.3–18.6) mmHg
respectively.
It is not entirely understood why acromegalic patients
have thicker corneas than healthy subjects. Visceromegaly
is a common clinical feature of acromegaly attributed to the
growth-promoting chronic effect of the GH on many or-
gans. The eye seems to be a target site for GH action, and
GH may have endocrine, autocrine or paracrine roles in
ocular development and growth. Thus, it is conceivable that
corneal tissue is a target for GH action. It is noteworthy that
Ciresi and coworkers [14] observed a strong linear correla-
tion between CCT and GH levels in a group of 28 patients
with acromegaly. Our study did not find a statistically
significant correlation between CCT and GH plasma levels.
This lack of correlation may be due to the small sample size
and the inevitable data scatter. The relationship between
CCT and GH requires further research in a larger cohort of
patients with acromegaly. Confounding factors may include
previous treatments (radiotherapy, medical, or surgical
therapies) and lack of documented GH and IGF-1 plasma
levels at diagnosis.
In common with previous reports, a limitation of the pres-
ent study is the small sample size due to the rarity of the
disease (Table 3). A potential bias of our study is related to
the fact that most our patients were on treatment with somato-
statin analogues which may have impacted ocular tissues
regardless of control of GH hypersecretion, as already dem-
onstrated for other clinical investigations [29–31]. Further
controlled studies are needed to better delineate the impact
of GH upon ocular tissues.
In conclusion, our data suggest that acromegaly is
associated with increased CCT that could lead to an
overestimation of IOP readings as determined by GAT
and possibly future glaucoma development risk. There-
fore, CCT evaluation should be considered an important
component of the ophthalmic assessment in acromegalic
patients.
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